AR073435A1 - Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine - Google Patents

Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Info

Publication number
AR073435A1
AR073435A1 ARP070104457A ARP070104457A AR073435A1 AR 073435 A1 AR073435 A1 AR 073435A1 AR P070104457 A ARP070104457 A AR P070104457A AR P070104457 A ARP070104457 A AR P070104457A AR 073435 A1 AR073435 A1 AR 073435A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
modified release
nsaid
combination
relaxing muscle
Prior art date
Application number
ARP070104457A
Other languages
English (en)
Inventor
Hernandez Gustavo Barranco
Paniagua Angelica Arzola
Lopez Enrique Raul Garcia-Salgado
Lopez Luis Fernando Poot
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of AR073435A1 publication Critical patent/AR073435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Abstract

Composicion farmacéutica de liberacion modificada en cápsulas con microesferas recubiertas que comprende la combinacion de dos principios activos de tiempos de concentracion plasmática radicalmente diferentes, éstos son un musculo relajante(tizanidina) y un analgésico antiinflamatorio no esteroide (meloxicarn), vehículos o excipientes farmacéuticamente aceptables; así como a un proceso para la manufactura de la composicion y al uso de dicha combinacion para la preparacion de unmedicamento con actividad terapéutica sinérgica indicada en el tratamiento de espasticidad, desordenes relacionados con padecimientos musculares y/o musculo esquelético y dolor en general de moderado o severo.
ARP070104457A 2006-10-18 2007-10-09 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine AR073435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06012024 2006-10-18

Publications (1)

Publication Number Publication Date
AR073435A1 true AR073435A1 (es) 2010-11-10

Family

ID=39313650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104457A AR073435A1 (es) 2006-10-18 2007-10-09 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Country Status (16)

Country Link
US (1) US20100166856A1 (es)
EP (1) EP2085076B1 (es)
AR (1) AR073435A1 (es)
AT (1) ATE499089T1 (es)
BR (1) BRPI0718368A2 (es)
CA (1) CA2670690C (es)
CL (1) CL2007002975A1 (es)
CO (1) CO6140021A2 (es)
CR (1) CR10801A (es)
DE (1) DE602007012751D1 (es)
EC (1) ECSP099348A (es)
ES (1) ES2361883T3 (es)
GT (1) GT200900089A (es)
PE (1) PE20081464A1 (es)
UY (1) UY30636A1 (es)
WO (1) WO2008047208A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009332963B2 (en) 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
WO2011034554A1 (en) * 2009-09-17 2011-03-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
PL2338473T3 (pl) 2009-12-18 2017-07-31 Mdm S.P.A. Postacie farmaceutycznej dawki tizanidyny i drogi jej podawania
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
EP2841072A4 (en) * 2012-04-27 2016-01-06 Troy Lab Pty Ltd POLYTHERAPY FOR ANIMALS BASED ON MELOXICAM AND XYLAZINE
US20170189374A1 (en) * 2014-07-21 2017-07-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Zaltoprofen and muscle relaxant combinations
WO2016193880A1 (en) * 2015-05-29 2016-12-08 Jubilant Generics Limited Immediate release pharmaceutical composition of tizanidine
US20190060287A1 (en) * 2017-08-28 2019-02-28 Adare Pharmaceuticals, Inc. Tizanidine formulations
CN113398096A (zh) * 2021-06-27 2021-09-17 烟台大学 一种含有美洛昔康的长效注射微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
ATE380022T1 (de) * 2001-01-31 2007-12-15 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
US8502335B2 (en) 2009-07-29 2013-08-06 Taiwan Semiconductor Manufacturing Company, Ltd. CMOS image sensor big via bonding pad application for AlCu Process

Also Published As

Publication number Publication date
CR10801A (es) 2009-07-03
CL2007002975A1 (es) 2008-01-04
EP2085076A1 (en) 2009-08-05
ATE499089T1 (de) 2011-03-15
EP2085076A4 (en) 2010-03-17
ES2361883T3 (es) 2011-06-24
GT200900089A (es) 2012-01-13
CO6140021A2 (es) 2010-03-19
CA2670690C (en) 2014-12-30
US20100166856A1 (en) 2010-07-01
PE20081464A1 (es) 2008-12-31
EP2085076B1 (en) 2011-02-23
UY30636A1 (es) 2008-05-02
WO2008047208A1 (es) 2008-04-24
BRPI0718368A2 (pt) 2013-11-12
CA2670690A1 (en) 2008-04-24
ECSP099348A (es) 2009-06-30
DE602007012751D1 (de) 2011-04-07

Similar Documents

Publication Publication Date Title
AR073435A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
Colla et al. Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
Kaster et al. Novel approaches for the management of depressive disorders
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
WO2006069293A3 (en) Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
Bastos et al. Drug repositioning: playing dirty to kill pain
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
Silva et al. Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
RU2014129508A (ru) Новая комбинация
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
Ionescu et al. Current trends in identifying rapidly acting treatments for depression
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
JP2016505050A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure